Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 6, 03 August 2023


Open Access | Article

Current drug treatments for Alzheimer's disease

Changjing Long * 1
1 Maple Leaf International School in Chongqing

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 6, 136-139
Published 03 August 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Changjing Long. Current drug treatments for Alzheimer's disease. TNS (2023) Vol. 6: 136-139. DOI: 10.54254/2753-8818/6/20230198.

Abstract

Alzheimer's disease (AD) is one of the four biggest killers of the elderly, along with heart disease, lung cancer and cerebrovascular disease. However, the current understanding of the underlying causes and treatment of AD is based only on some hypotheses, which makes our research on AD urgent. Based on the common inducing hypotheses of Alzheimer's disease, such as β-amyloid deposition hypothesis, tau protein phosphorylation hypothesis, and viral infection hypothesis, this article will search and summarize a variety of specific drugs for different pathological hypotheses in the medical community, including those that have been marketed and those that have shown good therapeutic effects in clinical trials. Find, understand and analyze the advantages and disadvantages of each specific drug, so as to better and faster help to study the latest specific drug for Alzheimer's disease, and change the quality of life and physical condition of people with Alzheimer's disease and their families.

Keywords

specific drugs, tau protein, beta-amyloid, Alzheimer's disease, development

References

1. Tiwari, S., et al., <p>Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics</p>. 2019. Volume 14: p. 5541-5554.

2. Schneider, L., A resurrection of aducanumab for Alzheimer's disease. Lancet Neurol, 2020. 19(2): p. 111-112.

3. Ostrowitzki, S., et al., A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer's Research & Therapy, 2017. 9(1).

4. Mark A. Mintun, M.D., Albert C. Lo, M.D., Ph.D., Cynthia Duggan Evans, Ph.D., Alette M. Wessels, Ph.D., Paul A. Ardayfio, Ph.D., Scott W. Andersen, M.S., Sergey Shcherbinin, Ph.D., JonDavid Sparks, Ph.D., John R. Sims, M.D., Miroslaw Brys, M.D., Ph.D., Liana G. Apostolova, M.D., Stephen P. Salloway, M.D., and Daniel M. Skovronsky, M.D., Ph.D,Donanemab in Early Alzheimer’s Disease. May 6, 2021

5. Kerchner, G.A., et al., [O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD. Alzheimer's & Dementia, 2017. 13(7S_Part_12).

6. Yu Zhang and Lu Fu, Advances in Alzheimer's disease immunotherapy targeting Aβ and Tau. Chin J Immunology, 2022.38 (05): 626-631.

7. Panza, F., et al., Time to test antibacterial therapy in Alzheimer’s disease. Brain, 2019.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
ISBN (Print)
978-1-915371-65-2
ISBN (Online)
978-1-915371-66-9
Published Date
03 August 2023
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/6/20230198
Copyright
03 August 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated